PP175 - EFFICACY OF A 12-SESSION TELE-CBT ON FOOD ADDICTION, METABOLIC OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH SEVERE OBESITY AND COMORBID FOOD ADDICTION: THE ADALOB RANDOMIZED CONTROLLED TRIAL

PP175

EFFICACY OF A 12-SESSION TELE-CBT ON FOOD ADDICTION, METABOLIC OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH SEVERE OBESITY AND COMORBID FOOD ADDICTION: THE ADALOB RANDOMIZED CONTROLLED TRIAL

R. Thibault^1,*, A. DeLuca², S. Barrault³, J. Léger⁴, P. Brunault⁵ on behalf of The ADALOB study group

¹Unité de Nutrition, CHU Rennes, INRAE, INSERM, Univ Rennes, Nutrition Metabolisms and Cancer Institute, NuMeCan, Rennes, ²CHRU de Tours, Centre Spécialisé pour la prise en charge de l’Obésité Sévère, 2 boulevard Tonnellé, ³Université de Tours, QualiPsy, UR 1901, ⁴Inserm CIC 1415, University Hospital of Tours, ⁵Addiction & Psychiatry, CHRU de Tours, Département d'Addictologie, Équipe de Liaison et de Soins en Addictologie, Tours, France

Rationale: Food addiction (FA) is prevalent in persons with severe obesity and is associated with negative outcomes. Studies conducted outside the field of obesity have demonstrated that Cognitive and Behavioral Therapy may be effective in treating FA, but studies conducted in patients with obesity and using tele-health are lacking.

Objective: To compare the short and medium-term efficacy of a 12-session tele-CBT (vs. a control group) on FA prevalence and symptoms, BMI and quality of life in treatment-seeking patients with severe obesity and a comorbid FA.

Methods: This randomized-control trial conducted in 9 French Nutrition Centers included 154 patients (77 CBT + treatment as usual, 77 treatment as usual) seeking a medical treatment for their obesity. Patients were assessed for FA (YFAS 2.0), BMI, metabolic syndrome and quality of life (QOLOD) at baseline, 6 weeks, 18 weeks (end of CBT) and 9 months.

Results: Mean BMI at baseline were 43.0±6.0 (CBT) and 42.6±5.9 (control group). CBT was associated with a significant reduction in FA prevalence compared to the control group at 18 weeks (29.2% vs. 49.6%; p<.02), but not at 6 weeks (45.4% vs. 56%; p=.22). Results were maintained at 9 months (number of FA symptoms=1.6±2.3 in CBT vs. 3.2±3.0 in control group; p<.001). CBT was associated with an improvement in quality of life, but not in BMI nor metabolic syndrome. 81.8% participated to the whole 12-session CBT program, with high acceptability and feasibility.

Conclusion: Tele-CBT is a feasible and effective treatment for improving FA in patients seeking treatment for obesity when a comorbid FA is identified. Future treatment should test the efficacy of CBT in combination with other treatments in order to achieve improvement in both FA and metabolic outcomes.

Disclosure of Interest: None declared